RSV-IN-1

Research use only, not for human use.

RSV-IN-1 is an inhibitor of human respiratory syncytical virus (hRSV) and reduced the virus infectivity with IC50 value of 0.11 μM.

RSV-IN-1 is an inhibitor of human respiratory syncytical virus (hRSV) and reduced the virus infectivity with IC50 value of 0.11 μM.(In Vitro):The concentration of RSV-IN-1 that reduced the viability of HEp-2 cells by 50% was 310μM. RSV-IN-1 exhibited no direct virucidal activity or inhibitory effects on the virus attachment to cells. However, to inhibit formation of RSV-induced syncytial plaques RSV-IN-1 had to be present during the virus entry into the cells and the cell-to-cell transmission of the virus. The RSV multiplication in HEp-2 cells in the presence of RSV-IN-1 resulted in rapid selection of viral variants that were ～1000 times less sensitive to these drugs than original virus.

The concentration of P13 that reduces the number of RSV plaques in HEp-2 cells by 50% (IC50) is 0.11 μM. The concentration of P13 that reduces the viability of HEp-2 by 50% (CC50) is 310 μM. Note that some cytotoxicity of P13 observed at 500 μM might be due to DMSO solvent. Hence, the selective index (CC50/IC50) values is 2818 for P13. Note that even at the relatively high concentrations P13 does not completely block the development of RSV plaques. These escape plaques are of smaller size and of non-syncytial phenotype as compared to plaques formed in the absence of inhibitor.

——

——

JAK/STAT Signaling

STAT

Androgen Receptor

——

——

861139-16-4

427.48

C20H21N5O4S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (233.93 mM)

COc1ccc(cc1-c1nnc2c3ccccc3c(C)nn12)S(=O)(=O)N(C)CCO

——

(-20℃)

With Ice Pack

≥ 2 years